Open AccessDoes COVID-19 cause an increased risk of hospitalization or death in patients with inflammatory rheumatic diseases treated with biological DMARDs or targeted synthetic DMARDs?
Author(s) -
May Lwin,
Christopher Holroyd,
Dinny Wallis,
Brian Davidson,
Lyndsey Goulston,
Hans de Graaf,
Christopher J Edwards
Publication year - 2020
Publication title -
rheumatology advances in practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.539
H-Index - 4
ISSN - 2514-1775
DOI - 10.1093/rap/rkaa061
Subject(s) - medicine , covid-19 , antirheumatic agents , tocilizumab , intensive care medicine , arthritis , rheumatoid arthritis , disease , infectious disease (medical specialty)
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom